COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Nov 9, 2022

Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer USA - English USA - English

Jan 14, 2022

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt technology

Nov 15, 2021

Oblique Therapeutics is thrilled to strengthen its commercial teams to realize its ambitious goals

Oct 14, 2021

Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 - 14, Washington DC, USA

Sep 28, 2021

Oblique Therapeutics announces achievement of key milestone in its aKRAS-mAb program and Abiprot platform

For More Press Releases

---